Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Vascularized Blood-Brain Barrier Model for In Vitro Testing of Drug and Immunotherapy Delivery

Award Number: R43NS132676
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2024

Group Awards By:

View Award Description

A Vascularized Blood-Brain Barrier Model for In Vitro Testing of Drug and Immunotherapy Delivery - PROJECT SUMMARY The brain is a highly-specialized, finely-tuned organ that depends for its function on maintaining homeostasis within narrowly-defined limits. This is achieved in large part by the Blood-Brain Barrier (BBB), which tightly regulates what can and can’t get into the brain. Functionally, the BBB is the combined work of endothelial cells (EC), pericytes and astrocytes, the latter two of which act on the EC to maintain an extensive network of tight junctions, promote the expression of specialized transporters, and limit the rate of transcellular pinocytosis. This lack of free transfer between blood and brain for non-lipophilic species severely limits the entry of many, otherwise useful, small molecule drugs. For example, cisplatin (<3% Brain/Plasma ratio), is effective in non-brain tumors, but has poor penetrance and low efficacy against brain tumors such as glioma. Similarly, delivery of immunotherapeutics such as bevacizumab (0.2%) and bi-specific antibodies is also limited, and much is still to be understood regarding the delivery of immune cells to the brain, including CAR-Ts, NK cells, γδ T cells and the patient’s own monocytes and lymphocytes. Finally, there are significant differences between mouse and human physiology including in the immune system. Many drug developers are therefore turning to human cell- based systems rather than mouse models. The primary goal of this Phase I SBIR application is to demonstrate the feasibility of Aracari Biosciences’ proprietary technology to model appropriate drug and immunotherapeutic delivery across the human BBB. Aracari’s patented core technology is a perfusable human vascular network within a microfluidic device that fits in a convenient 96-well plate format. This technology has been successfully developed into commercialized products including the vascularized micro-organ (VMOTM) and the vascularized micro-tumor (VMTTM). Importantly, leukocytes can be perfused through the vessels and on stimulation they will adhere and extravasate as they do in vivo. We have also developed a vascularized micro-brain (VMB), which is the focus of this application. This incorporates a perfused neurovascular unit (NVU) comprised of human BBB EC, pericytes and astrocytes, all embedded in a brain-mimicking extracellular matrix. The vessels show upregulation of BBB transporters and junctional proteins, and greatly-reduced permeability compared to non- NVU vessels. Tumor cells (glioma) can be added to model brain tumors (VMB-T) and the potential compromise of the BBB. This model will provide unprecedented opportunities to study drug responses of glioma and other brain tumors in a more natural environment. Our preliminary data show the feasibility of our goals which are: Specific Aim 1: Characterize permeability of a small panel of brain-targeted drugs in the VMB and VMB-T Specific Aim 2: Characterize delivery of a small panel of immunotherapeutic drugs in the VMB and VMB-T Specific Aim 3: Characterize delivery of immune cells in the VMB and VMB-T Completion of these aims will provide us with a unique tool we can offer to pharmaceutical companies for studies on BBB properties, and delivery of neuroactive drugs and immuno-oncology drugs and cells.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $294,998 )
2023	2023	ARACARI BIOSCIENCES INC	5270 CALIFORNIA AVE	IRVINE	CA	92617	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	4/24/2023	NEW	$294,998
														Subtotal = $294,998

Grand Total All Awards = $294,998

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Vascularized Blood-Brain Barrier Model for In Vitro Testing of Drug and Immunotherapy Delivery

Award Number: R43NS132676

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer